These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 16868082)

  • 41. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilars lining up to compete with Herceptin--opportunity knocks.
    Nelson KM; Gallagher PC
    Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnetic-resonance imaging for kinetic analysis of permeability changes during focused ultrasound-induced blood-brain barrier opening and brain drug delivery.
    Chai WY; Chu PC; Tsai MY; Lin YC; Wang JJ; Wei KC; Wai YY; Liu HL
    J Control Release; 2014 Oct; 192():1-9. PubMed ID: 24969355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery.
    Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J
    Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted drug delivery to the brain using focused ultrasound.
    Kinoshita M
    Top Magn Reson Imaging; 2006 Jun; 17(3):209-15. PubMed ID: 17414078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Trastuzumab and blood-brain barrier].
    Platini C
    Bull Cancer; 2007 Oct; 94(10):857-9. PubMed ID: 17964978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
    Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
    Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Adjuvant therapy of breast cancer with trastuzumab].
    Beneder C; Marth C
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):138-42. PubMed ID: 18566530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound.
    Treat LH; McDannold N; Vykhodtseva N; Zhang Y; Tam K; Hynynen K
    Int J Cancer; 2007 Aug; 121(4):901-7. PubMed ID: 17437269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
    Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
    Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography].
    Hattori K; Nishi Y; Nakamura S; Misao H; Kikuchi M; Sasaki R; Takeda K
    Rinsho Byori; 2007 Feb; 55(2):120-5. PubMed ID: 17390714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption.
    Vykhodtseva N; McDannold N; Hynynen K
    Ultrasonics; 2008 Aug; 48(4):279-96. PubMed ID: 18511095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Focused ultrasound for blood-brain disruption and delivery of therapeutic molecules into the brain.
    Hynynen K
    Expert Opin Drug Deliv; 2007 Jan; 4(1):27-35. PubMed ID: 17184160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases.
    O'Reilly MA; Chinnery T; Yee ML; Wu SK; Hynynen K; Kerbel RS; Czarnota GJ; Pritchard KI; Sahgal A
    Sci Rep; 2018 Jun; 8(1):9013. PubMed ID: 29899537
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Focused ultrasound blood brain barrier opening mediated delivery of MRI-visible albumin nanoclusters to the rat brain for localized drug delivery with temporal control.
    Rich MC; Sherwood J; Bartley AF; Whitsitt QA; Lee M; Willoughby WR; Dobrunz LE; Bao Y; Lubin FD; Bolding M
    J Control Release; 2020 Aug; 324():172-180. PubMed ID: 32376461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.